Matthew Scholz
Founder and Chief Executive Officer at Oisín Biotechnologies
Matthew Scholz is the founder and Chief Executive Officer of Immusoft, a biotech start-up firm that is developing a breakthrough technology that will turn a patient’s B cells into miniature drug factories. Longer term, this technology has the potential to transform the landscape of biomedicine.
See also: Oisin Biotechnologies - Drug development company focused on the senolytic technology to fight age-related diseases
Details last updated 15-May-2020
Matthew Scholz News
Oisín Biotechnologies' gene therapy may be available in the next 5 years
Longevity Technology - 22-Jan-2021
Results in mice suggest that it can increase median lifespan in humans by 15 years
Read more...Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Read more...OncoSenX raises more funds for cancer therapy, plans for clinical trial
GeekWire - 11-May-2020
Allowing developments on tech that will kill cancer based on their genetics
Read more...Oisín made it to top 10 breakthrough technologies of 2020
Business Wire - 26-Feb-2020
Will begin clinical trials after completing pre-clinical studies
Read more...